You are here: Industry Insights > ADCC

News List

ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology b3cnewswire
February 11, 2022
ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology.
ProBioGen's GlymaxX® Technology Reaches Phase III Clinical Development B3Cnewswire
December 20, 2021
ProBioGen, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for its GlymaxX antibody-dependent cellular cytotoxicity (ADCC) enhancement technology.
ProBioGen's GlymaxX® Technology Made It Again into Clinical Phase I B3Cnewswire
November 18, 2021
ProBioGen, a premier CDMO for cell line development through GMP manufacturing which has also developed innovative technologies, announced that another product candidate applying its antibody-dependent cellular cytotoxicity...
AbbVie Licenses ProBioGen’s GlymaxX Technology contractpharma
January 26, 2021
ProBioGen has signed a commercial license agreement with AbbVie to apply ProBioGen's GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-Enhanced CD20 Monoclonal Antibody americanpharmaceuticalreview
December 10, 2018
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun in a Phase I clinical study of BAT4306F in....